First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study
Cancer Medicine · 2024
DOI: 10.1002/cam4.6843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Thomas Bardol und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Axl Receptor Tyrosine Kinase, Receptor Protein-Tyrosine Kinases, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MUSE grant "KIM Biomarkers and therapy", University of Montpellier.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
For several years, the AXL tyrosine kinase receptor, a member of the Tyro3‐Axl‐Mer (TAM) family, has been considered a new strategic target in oncology. AXL overexpression is common in solid tumors and is associated with poor prognosis. In this context, the detection of a subset of circulating tumor cells (CTCs) that express AXL (AXL + CTCs) could be clinically relevant.
Methods
Immunostaining was performed to assess AXL expression in human breast cancer cell lines. The optimal conditions were established using flow cytometry. Spiking experiments were carried out to optimize the parameters of the CellSearch ® system detection test. CTC enumeration and AXL expression were evaluated in patients with metastatic breast cancer (mBC) before treatment initiation.
Results
An innovative AXL + CTC detection assay to be used with the CellSearch ® system was developed. In a prospective longitudinal clinical trial, blood samples from 60 patients with untreated mBC were analyzed to detect AXL + CTCs with this new assay. CTCs were detected in 35/60 patients (58.3%) and AXL + CTCs were identified in 7 of these 35 patients (11.7% of all patients).
Conclusion
This newly established AXL + CTC assay is a promising tool that can be used for liquid biopsy in future clinical trials to stratify and monitor patients with cancer receiving anti‐AXL therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.
- CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France.
- European Liquid Biopsy Society (ELBS), Hamburg, Germany.
- Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.
- Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France.
ORCID-Profile: Thomas Bardol
Förderung
- MUSE grant "KIM Biomarkers and therapy", University of Montpellier
Zitieren
APA
Bardol, T., Eslami-S, Z., Masmoudi, D., Alexandre, M., Duboys de Labarre, M., Bobrie, A., D'Hondt, V., Guiu, S., Kurma, K., Cayrefourcq, L., Jacot, W., & Alix-Panabières, C. (2024). First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study. Cancer Medicine. https://doi.org/10.1002/cam4.6843
Vancouver
Bardol T, Eslami-S Z, Masmoudi D, Alexandre M, Duboys de Labarre M, Bobrie A, et al. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study. Cancer Medicine. 2024. doi:10.1002/cam4.6843
BibTeX
@article{Bardol2024,
author = {Bardol, Thomas and Eslami-S, Zahra and Masmoudi, Doryan and Alexandre, Marie and Duboys de Labarre, Marie and Bobrie, Angélique and D'Hondt, Véronique and Guiu, Séverine and Kurma, Keerthi and Cayrefourcq, Laure and Jacot, William and Alix-Panabières, Catherine},
title = {First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.6843}
}
EUVIMED